MO
GSK icon

McMillan Office’s GSK GSK Stock Holding History

McMillan Office’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380K Hold
7,241
– – 0.04% 146
2026
Q1 		$400K Hold
7,241
– – 0.05% 131
2025
Q4 		$355K Buy
+7,241
New +$338K 0.04% 145

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

McMillan Office's GSK Position: Q2 2026 in Review

McMillan Office held its GSK (GSK) position steady in Q2 2026 at 7,241 shares worth $380K. The position accounts for 0.04% of the portfolio, ranked #146.

McMillan Office first reported a position in GSK in Q4 2025 and has held it in 3 quarters since. The position peaked at $400K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • McMillan Office held 7,241 shares of GSK worth $380K as of Q2 2026.
  • McMillan Office left its GSK share count unchanged in Q2 2026.
  • GSK made up 0.04% of McMillan Office's portfolio in Q2 2026, its #146 holding.
  • McMillan Office first reported a position in GSK in Q4 2025 and has held it in 3 quarters since.
  • McMillan Office's GSK position peaked at $400K in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.